Your browser is no longer supported. Please, upgrade your browser.
NTLA Intellia Therapeutics, Inc. daily Stock Chart
NTLA [NASD]
Intellia Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.11 Insider Own0.10% Shs Outstand50.13M Perf Week0.59%
Market Cap601.06M Forward P/E- EPS next Y-2.83 Insider Trans0.00% Shs Float40.74M Perf Month-21.63%
Income-99.50M PEG- EPS next Q-0.45 Inst Own77.40% Short Float26.16% Perf Quarter-17.96%
Sales43.10M P/S13.95 EPS this Y-6.30% Inst Trans0.02% Short Ratio14.05 Perf Half Y0.25%
Book/sh5.47 P/B2.19 EPS next Y-11.40% ROA-28.90% Target Price25.75 Perf Year-33.94%
Cash/sh5.58 P/C2.15 EPS next 5Y30.00% ROE-36.60% 52W Range9.18 - 19.00 Perf YTD-18.27%
Dividend- P/FCF- EPS past 5Y-50.60% ROI- 52W High-36.89% Beta1.76
Dividend %- Quick Ratio8.10 Sales past 5Y- Gross Margin- 52W Low30.61% ATR1.35
Employees270 Current Ratio8.10 Sales Q/Q38.00% Oper. Margin- RSI (14)47.28 Volatility9.26% 11.54%
OptionableYes Debt/Eq0.00 EPS Q/Q-32.90% Profit Margin- Rel Volume0.37 Prev Close11.90
ShortableYes LT Debt/Eq0.00 EarningsFeb 27 BMO Payout- Avg Volume758.23K Price11.99
Recom2.00 SMA20-1.30% SMA50-8.12% SMA200-16.99% Volume280,706 Change0.76%
Feb-28-20Upgrade Oppenheimer Perform → Outperform
Feb-14-20Downgrade Wedbush Outperform → Neutral $16
Nov-01-19Upgrade Raymond James Mkt Perform → Outperform
Jul-09-19Initiated Robert W. Baird Outperform $23
Jun-10-19Initiated ROTH Capital Neutral $16
May-03-19Upgrade Wedbush Neutral → Outperform $20 → $21
Apr-12-19Initiated Evercore ISI Outperform
Nov-02-18Downgrade Wedbush Outperform → Neutral $36 → $20
Oct-29-18Initiated Credit Suisse Neutral $24
Sep-21-18Initiated Raymond James Mkt Perform
May-15-18Upgrade Chardan Capital Markets Neutral → Buy $20 → $57.50
Mar-08-18Initiated JMP Securities Mkt Outperform $76
Nov-01-17Reiterated Jefferies Buy $36 → $42
Jun-22-17Resumed Jefferies Buy $36
Mar-28-17Initiated Chardan Capital Markets Buy $19
Aug-05-16Upgrade Jefferies Hold → Buy
May-31-16Initiated Wedbush Outperform $38
May-31-16Initiated Leerink Partners Mkt Perform
May-31-16Initiated Jefferies Hold $33
May-31-16Initiated Credit Suisse Outperform $39
Mar-31-20 07:30AM  FDA Accepts Investigational New Drug Application for CRISPR/Cas9-Based Sickle Cell Disease Therapeutic Candidate Developed Under Collaboration with Intellia Therapeutics GlobeNewswire
Mar-24-20 04:19PM  Edited Transcript of NTLA earnings conference call or presentation 27-Feb-20 1:00pm GMT Thomson Reuters StreetEvents
Feb-27-20 08:55AM  Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates Zacks -5.57%
07:30AM  Intellia Therapeutics Announces Fourth Quarter and Full-Year 2019 Financial Results GlobeNewswire
Feb-20-20 10:53AM  Intellia (NTLA) to Report Q4 Earnings: What's in Store? Zacks
07:30AM  Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2019 Earnings and Company Update GlobeNewswire
Feb-19-20 12:31PM  Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q4 Earnings Expected to Decline Zacks
Feb-12-20 09:33AM  Here's Why We're Not Too Worried About Intellia Therapeutics's (NASDAQ:NTLA) Cash Burn Situation Simply Wall St.
Feb-10-20 07:30AM  Intellia Therapeutics Presents New Data From Its Engineered Cell Therapy and In Vivo Programs at Keystone Symposias Engineering the Genome Conference GlobeNewswire +9.40%
Feb-07-20 08:54AM  Implied Volatility Surging for Intellia (NTLA) Stock Options Zacks
Jan-17-20 02:09PM  European ruling threatens Broad's CRISPR gene-editing patents American City Business Journals
Jan-09-20 07:30AM  Intellia Therapeutics Highlights Recent Progress and Anticipated 2020 Milestones GlobeNewswire
Jan-06-20 11:00PM  Crispr puts first human in-body gene editing to test Financial Times
Dec-30-19 04:07PM  Gene-Editing Stocks Dive As Creator Of CRISPR Babies Sent To Prison Investor's Business Daily
03:40PM  Axsome Therapeutics jumps as migraine drug hits goals in late-stage trial Yahoo Finance Video
Dec-25-19 11:30AM  Has Intellia Therapeutics (NTLA) Outpaced Other Medical Stocks This Year? Zacks
Dec-17-19 06:00AM  Atlas, MPM, Partners funnel $49M into a new gene-silencing startup American City Business Journals
Dec-14-19 09:13PM  Did Hedge Funds Drop The Ball On Intellia Therapeutics, Inc. (NTLA) ? Insider Monkey
Dec-10-19 10:38AM  Did Intellia Therapeutics, Inc. (NASDAQ:NTLA) Insiders Buy Up More Shares? Simply Wall St.
Dec-05-19 03:49AM  Gene Therapy the Next Best Thing: Here's Why (Revised) Zacks
Dec-04-19 09:42AM  Gene Therapy the Next Best Thing: Here's Why Zacks
Dec-03-19 01:03AM  Don't Judge a Month by its First Day Zacks
Dec-02-19 06:33AM  Novartis-linked biotech firm raises $56M for new spinouts American City Business Journals
Nov-26-19 08:00AM  Intellia Therapeutics to Present at Evercore ISI 2nd Annual HealthCONx Conference GlobeNewswire
Nov-20-19 03:11PM  Edited Transcript of NTLA earnings conference call or presentation 31-Oct-19 12:00pm GMT Thomson Reuters StreetEvents
09:12AM  Vertex, CRISPR's Gene Editing Drug Shows Positive Early Data Zacks
01:05AM  The NASDAQ Needs No Break Zacks
Nov-19-19 10:46AM  CRISPR Therapeutics stock jumps on early gene editing data American City Business Journals +10.15%
09:40AM  Axovant's GM1 Gangliosidosis Candidate Gets Orphan Drug Tag Zacks
Nov-13-19 01:01AM  NASDAQ Hits New Record Despite Slow Session Zacks
Nov-07-19 09:44AM  Intellia Therapeutics, Inc. (NTLA) Shares March Higher, Can It Continue? Zacks
06:08AM  These 36 Mass. firms made Deloitte's Technology Fast 500 American City Business Journals
Oct-31-19 09:15AM  Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Tops Revenue Estimates Zacks +6.07%
07:30AM  Intellia Therapeutics Announces Third Quarter 2019 Financial Results GlobeNewswire
04:30AM  8 Undervalued Biotech Stocks to Watch Now Investopedia
Oct-30-19 08:34PM  Hedge Funds Have Never Been This Bullish On Intellia Therapeutics, Inc. (NTLA) Insider Monkey
Oct-29-19 04:05PM  Experts Talk Hot Biotech Stocks at Barrons Breakfast Barrons.com
Oct-24-19 08:00AM  Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2019 Earnings and Company Update GlobeNewswire
07:30AM  Intellia Therapeutics Presents In Vivo and Ex Vivo Data at the 2019 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT) GlobeNewswire
Oct-23-19 10:33AM  Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q3 Earnings Expected to Decline Zacks
Oct-16-19 08:00AM  Intellia Therapeutics Announces Presentations at the 2019 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT) GlobeNewswire
Oct-07-19 06:00AM  New Cambridge biotech Korro aims to develop a reversible form of gene editing American City Business Journals
Sep-30-19 08:00AM  Intellia Therapeutics to Present at October Healthcare Investor Conferences GlobeNewswire
Sep-26-19 04:30PM  Arbitration Decision Affirms Intellia Therapeutics Interpretation of Licensing Agreement with Caribou Biosciences on the CRISPR/Cas9 Technology GlobeNewswire -5.01%
Sep-11-19 01:18PM  Introducing Intellia Therapeutics (NASDAQ:NTLA), The Stock That Slid 52% In The Last Year Simply Wall St. +5.77%
Aug-06-19 05:43AM  Edited Transcript of NTLA earnings conference call or presentation 1-Aug-19 12:00pm GMT Thomson Reuters StreetEvents
Aug-01-19 12:23PM  Intellia Therapeutics, Inc. (NTLA) Q2 2019 Earnings Call Transcript Motley Fool
08:55AM  Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:30AM  Intellia Therapeutics Announces Second Quarter 2019 Financial Results and Company Update GlobeNewswire
06:16AM  Legal fight over Broad Institute's patent for CRISPR gene editing flares up again American City Business Journals
Jul-31-19 12:41PM  Is Intellia Therapeutics a Buy? Motley Fool
Jul-30-19 08:00AM  Intellia Therapeutics to Present at August Healthcare Investor Conference GlobeNewswire
Jul-25-19 07:30AM  Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2019 Earnings and Company Update GlobeNewswire
Jul-10-19 08:16AM  Here's Why CRISPR Gene Editing Stocks Rose as Much as 32.4% in June Motley Fool
Jul-09-19 10:49AM  Baird: Preclinical Data Inspires 'Early Optimism' In Lead Intellia Therapeutics Asset Benzinga
Jul-05-19 08:57AM  Editas (EDIT) Focuses on Developing Eye Candidate EDIT-101 Zacks
Jun-29-19 08:22PM  Here is What Hedge Funds Think About Intellia Therapeutics, Inc. (NTLA) Insider Monkey
Jun-14-19 09:00AM  Glaxo Inks Genome Research Deal With University of California Zacks
Jun-10-19 07:47AM  How Many Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Did Insiders Buy, In The Last Year? Simply Wall St.
May-30-19 04:30PM  Intellia Therapeutics to Participate at June Healthcare Investor Conferences GlobeNewswire
May-28-19 07:50AM  Intellia Therapeutics Names Laura Sepp-Lorenzino, Ph.D., Chief Scientific Officer GlobeNewswire
May-09-19 07:20PM  Is Intellia Therapeutics, Inc. (NTLA) A Good Stock To Buy? Insider Monkey
May-07-19 04:01PM  Edited Transcript of NTLA earnings conference call or presentation 2-May-19 12:00pm GMT Thomson Reuters StreetEvents -7.66%
May-06-19 06:05PM  3 Biotech Sector ETFs Bucked the Risk-Off Trend ETF Trends +10.49%
May-02-19 01:16PM  Intellia Therapeutics, Inc. (NTLA) Q1 2019 Earnings Call Transcript Motley Fool
09:15AM  Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Lags Revenue Estimates Zacks
07:30AM  Intellia Therapeutics Announces First Quarter 2019 Financial Results and Company Update GlobeNewswire
Apr-29-19 07:30AM  Intellia Therapeutics Presents New In Vivo and Engineered Cell Therapy Data at the 22nd Annual Meeting of the American Society of Gene and Cell Therapy GlobeNewswire
Apr-25-19 07:30AM  Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2019 Earnings and Company Update GlobeNewswire
Apr-17-19 01:10PM  One-Size-Fits-All CRISPR Lock Could Catapult the Sector Forward GuruFocus.com -6.79%
07:14AM  Vertex, CRISPR's Gene Editing Drug Gets FDA's Fast Track Tag Zacks
Apr-15-19 04:30PM  Intellia Therapeutics Announces Three Oral Presentations on In Vivo and Engineered Cell Therapy Data at the 22nd Annual Meeting of the American Society of Gene and Cell Therapy GlobeNewswire
Apr-09-19 03:33PM  These Cannabis and China ETFs are Leading the 2019 Rally Investopedia -5.06%
Apr-03-19 04:11PM  CRISPR Biotech Inks Deal To Use Stem Cells In Gene-Editing Medicine Investor's Business Daily
Mar-12-19 07:34AM  Some Intellia Therapeutics (NASDAQ:NTLA) Shareholders Have Copped A Big 50% Share Price Drop Simply Wall St.
Mar-07-19 02:47PM  5 Top Gene-Editing Stocks for 2019 Motley Fool
Mar-01-19 04:54PM  Intellia CEO not involved in Starboard's Bristol-Myers board challenge Reuters +11.10%
03:20PM  A Specialty Biotech ETF Strengthens on Optimism Over CRISPR Advancements ETF Trends
01:57PM  Intellia CEO not involved in Starboard's Bristol-Myers board challenge Reuters
Feb-28-19 07:44PM  Intellia CEO not involved in Starboard's Bristol-Myers board challenge Reuters
Feb-27-19 06:30AM  Intellia Therapeutics Announces Fourth Quarter and Full-Year 2018 Financial Results GlobeNewswire +6.34%
Feb-26-19 10:54AM  CRISPR Therapeutics Up as Dosing Starts in Thalassemia Study Zacks
Feb-24-19 10:16AM  Better Buy: Editas Medicine vs. Intellia Therapeutics Motley Fool
Feb-06-19 07:50AM  Research Report Identifies Norfolk Southern, DENTSPLY SIRONA, Healthcare Realty Trust, PTC, Intellia Therapeutics, and El Paso Electric with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Feb-01-19 02:11PM  German firm that serves gene therapy biotechs opens Cambridge HQ American City Business Journals
01:53PM  3 Biotech Stocks That Are Set for a Breakthrough InvestorPlace
Jan-24-19 07:00AM  Intellia Therapeutics Names Fred Cohen, M.D., to Board of Directors GlobeNewswire
Jan-22-19 04:28PM  Editas CEO Resigns Sending All 3 CRISPR Stocks Into Free Fall Investor's Business Daily -6.84%
Jan-11-19 09:36AM  Here's Why Intellia Therapeutics Stock Lost 23.8% in December Motley Fool
Jan-10-19 03:36PM  The Best CRISPR Stock Gained 21% in 2018, While The Worst Lost 29% Motley Fool
Jan-07-19 10:03AM  Vertex, CRISPR's Sickle Disease Drug Gets FDA's Fast Track Tag Zacks
Jan-04-19 04:24PM  These Stocks Pop After FDA Expedites Review Of Gene-Editing Therapy Investor's Business Daily +6.93%
Dec-17-18 07:25AM  New Research: Key Drivers of Growth for Ashland Global, Intellia Therapeutics, Thor Industries, Zogenix, BWX Technologies, and Heidrick & Struggles International Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Dec-10-18 04:31PM  Why CRSP Stock Has Added Layers of Risk InvestorPlace
Dec-06-18 07:30AM  Intellia Therapeutics and Novartis Expand Cell Therapy Collaboration to Pursue CRISPR/Cas9-based Genome Editing in Additional Stem Cell Population GlobeNewswire
Nov-30-18 04:14PM  This Biotech Stock Could Launch Its First CRISPR Drug In 2022 Investor's Business Daily
10:31AM  Why Crispr Therapeutics Stock Is Up By 65% So Far in 2018 Motley Fool
09:15AM  The Market is All Packed for Buenos Aires Zacks
Nov-28-18 01:05PM  Leerink Starts Coverage Of Genetic Medicine Stocks: 'We See Commercial Execution As Increasingly Driving Returns' Benzinga +6.95%
Nov-26-18 04:22PM  With genetically edited babies, a scientist transgresses a moral boundary MarketWatch
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company develops in vivo programs focusing on liver diseases, including transthyretin amyloidosis and hereditary angioedema, as well as other research programs comprising primary hyperoxaluria Type 1, alpha-1 antitrypsin deficiency, and Hemophilia B. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells; and acute myeloid leukemia. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc.; Regeneron Pharmaceuticals, Inc.; and Ospedale San Raffaele. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.